Using this approach we have indentified six promising compounds out of 10,000 which significantly reduce levels of APP, Aβ40 and Aβ42 at lower concentrations, are non-cytotoxic, do not change the metabolic activity and fulfill the terms fur drug-likeness, which is a key fact for developing AD drugs. Here, APP is linked to Alzheimer disease.